NCT03419364View on ClinicalTrials.gov

Study of Nicotinamide in Early Onset Preeclampsia

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

August 31, 2021

Study Completion Date

August 31, 2021

Conditions
Pre-EclampsiaPregnancy Related
Interventions
DRUG

nicotinamide

2.5 gm nicotinamide given orally in 3 divided doses: 1000 mg in morning and evening, 500 mg at noon/midday

Trial Locations (1)

27599

UNC at Chapel Hill, Chapel Hill

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

University of North Carolina, Chapel Hill

OTHER

NCT03419364 - Study of Nicotinamide in Early Onset Preeclampsia | Biotech Hunter | Biotech Hunter